|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.05.26 - 11:06
|
William Blair Accelerates Investment in Biotech Equity Research and Equities Platform (Business Wire)
|
|
|
CHICAGO & NEW YORK--(BUSINESS WIRE)--William Blair today announced a strategic investment in its equities platform, expanding resources across biotech equity research and institutional sales and trading to support long-term client demand driven by sustained innovation and increasingly complex institutional strategies.
Alethia Young Joins Biotech Equity Research, Expanding Biotech Coverage
Alethia Young has joined William Blair's Biotech Equity Research team, reflecting the firm's strategic investment in biotech research as a core area of focus.
Alethia brings 25 years of experience across the biotechnology and healthcare industry, including roles as a sell-side analyst, chief financial officer, and independent board member. Before joining William Blair, she served as chief financial officer of Bicycle Therapeutics. Earlier in her career, Alethia was a sell-side equity research analyst at Cantor Fitzgerald, Credit Suisse, and Deutsche Bank. She holds a B.A. in economics from Duke University.
“Biotech r...
|
|
|
|
|
30.04.26 - 13:03
|
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results (Business Wire)
|
|
|
Presentations at AACR Annual Meeting 2026 underscore significant opportunities for nuzefatide pevedotin in EphA2 expressing cancers, including pancreatic cancer
Human imaging data provides further evidence of the potential of EphA2 as a novel cancer target and the positive properties of Bicycle® radioligand molecules for radiopharmaceutical use
Initial dose selection data from Duravelo-2 trial evaluating zelenectide pevedotin plus pembrolizumab in metastatic urothelial cancer to be presented at 2026 ASCO Annual Meeting
Cash and cash equivalents of $559.5 million as of March 31, 2026, with expected cash runway into 2030CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended March 31, 2026, and provided recent corporate updates.
“The data we reported in the first quar...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
